Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

Sugammadex and Heart Failure

Phase 3

Completed

Conditions: Postoperative Neuromuscular Block

Interventions: Drug: Sugammadex

First Posted Date: 2012-01-13

Last Posted Date: 2012-04-04

Lead Sponsor: Onze Lieve Vrouw Hospital

Target Recruit Count: 12

Registration Number: NCT01509651

Locations: 🇧🇪
OLV Hospital, Aalst, Belgium

Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis

Not Applicable

Completed

Conditions: Postoperative Residual Paralysis

Interventions: Drug: sugammadex
Drug: Sodium chloride solution

First Posted Date: 2012-01-04

Last Posted Date: 2014-04-22

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 20

Registration Number: NCT01503840

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Phase 3

Completed

Conditions: Surgical Procedures, Elective

Interventions: Drug: Sugammadex
Drug: Neostigmine
Drug: Glycopyrrolate

First Posted Date: 2011-11-24

Last Posted Date: 2017-06-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 154

Registration Number: NCT01479764

Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade

Phase 4

Conditions: Anesthesia Recovery Period

Interventions: Drug: Neostigmine/Glycopyrrolate
Other: Placebo
Drug: Sugammadex

First Posted Date: 2011-10-18

Last Posted Date: 2011-10-18

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT01453530

Locations: 🇳🇱
UMC Sint Radboud, Nijmegen, Gelderland, Netherlands

Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade

Phase 4

Conditions: Adult Subjects Undergoing Abdominal Surgery Under General Anesthesia

Interventions: Drug: placebo
Drug: sugammadex

First Posted Date: 2011-08-29

Last Posted Date: 2011-08-29

Lead Sponsor: Central Clinical Hospital #1 of LLC Russian Railways

Target Recruit Count: 42

Registration Number: NCT01424488

Locations: 🇷🇺
Central Clinical Hospital #1 of LLC "Russian Railroad", Moscow, Russian Federation

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Phase 3

Completed

Conditions: Neuromuscular Blockade
Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Knee
Blood Coagulation
Antithrombotic Agents

Interventions: Drug: Sugammadex
Drug: neostigmine and glycopyrrolate or atropine
Drug: Placebo to neostigmine
Drug: Placebo to sugammadex

First Posted Date: 2011-08-23

Last Posted Date: 2021-02-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1198

Registration Number: NCT01422304

Sugammadex: Effect on the Awareness Monitoring and Hemodynamics

Not Applicable

Conditions: Surgical Procedure, Unspecified

Interventions: Drug: Sugammadex 4 mg/kg
Drug: Sugammadex 16mg/kg
Drug: sugammadex

First Posted Date: 2011-02-23

Last Posted Date: 2012-06-19

Lead Sponsor: University of Athens

Target Recruit Count: 60

Registration Number: NCT01301261

Locations: 🇬🇷
Department of Anesthesiology, Aretaieio Hospital, Athens, Greece

Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)

Completed

Conditions: Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery

Interventions: Other: No neuromuscular blockade (NMB)-reversal agent used
Drug: Other NMB-Reversal Agents Used in Routine Anesthesiology Practice
Drug: Sugammadex

First Posted Date: 2010-10-01

Last Posted Date: 2015-03-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 659

Registration Number: NCT01213264

Sugammadex and Brain Waves

Phase 4

Completed

Conditions: Anaesthesia

First Posted Date: 2010-06-11

Last Posted Date: 2010-06-11

Lead Sponsor: Tampere University Hospital

Target Recruit Count: 30

Registration Number: NCT01142648

Locations: 🇫🇮
Tampere University Hospital, Tampere, Finland

Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Placebo
Drug: Sugammadex

First Posted Date: 2010-04-09

Last Posted Date: 2012-12-17

Lead Sponsor: Technical University of Munich

Target Recruit Count: 300

Registration Number: NCT01101139

Locations: 🇩🇪
Klinik für Anaesthesiologie Klinikum München rechts der Isar, Munic, Bavaria, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy